Curbstone Financial Management Corp Purchases Shares of 21,296 Hologic, Inc. (HOLX)

Curbstone Financial Management Corp purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,296 shares of the medical equipment provider’s stock, valued at approximately $847,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of HOLX. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Hologic during the first quarter valued at approximately $146,000. Synovus Financial Corp acquired a new stake in Hologic during the first quarter valued at approximately $164,000. IBM Retirement Fund acquired a new stake in Hologic during the first quarter valued at approximately $227,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Hologic during the fourth quarter valued at approximately $235,000. Finally, United Capital Financial Advisers LLC boosted its holdings in Hologic by 34.4% during the first quarter. United Capital Financial Advisers LLC now owns 6,395 shares of the medical equipment provider’s stock valued at $239,000 after purchasing an additional 1,638 shares in the last quarter. Hedge funds and other institutional investors own 93.34% of the company’s stock.

In other Hologic news, VP Karleen Marie Oberton sold 12,196 shares of the company’s stock in a transaction on Wednesday, May 2nd. The stock was sold at an average price of $40.00, for a total transaction of $487,840.00. Following the transaction, the vice president now owns 13,825 shares of the company’s stock, valued at approximately $553,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Peter J. Valenti III sold 10,107 shares of the company’s stock in a transaction on Tuesday, May 29th. The stock was sold at an average price of $38.52, for a total value of $389,321.64. The disclosure for this sale can be found here. 0.79% of the stock is owned by insiders.

Shares of Hologic opened at $41.09 on Friday, according to Marketbeat. The company has a market capitalization of $10.79 billion, a PE ratio of 20.24, a price-to-earnings-growth ratio of 1.86 and a beta of 0.82. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.98 and a current ratio of 1.26. Hologic, Inc. has a one year low of $35.10 and a one year high of $45.58.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 EPS for the quarter, hitting the consensus estimate of $0.53. The business had revenue of $789.30 million for the quarter, compared to the consensus estimate of $781.23 million. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. Hologic’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.50 EPS. sell-side analysts expect that Hologic, Inc. will post 2.23 EPS for the current fiscal year.

A number of research firms have weighed in on HOLX. Leerink Swann downgraded Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $48.00 to $41.00 in a report on Thursday, May 3rd. BTIG Research reaffirmed a “buy” rating and set a $44.00 price objective on shares of Hologic in a report on Sunday, May 6th. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a report on Monday, April 30th. Barclays decreased their price objective on Hologic from $54.00 to $50.00 and set an “overweight” rating on the stock in a report on Thursday, May 3rd. Finally, BidaskClub raised Hologic from a “sell” rating to a “hold” rating in a report on Friday, April 27th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $44.87.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply